公开(公告)号：EP4400117A1

公开(公告)日：2024-07-17

申请号：EP22867349.7

申请日：2022-09-06

申请人： Kyoto University

发明人： KONDOH Hiroshi ,  MIKAWA Takumi

IPC分类号： A61K45/00

CPC分类号： A61K31/08 ,  A61K31/138 ,  A61K31/166 ,  A61K31/352 ,  A61K31/366 ,  A61K31/407 ,  A61K31/409 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/437 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/444 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/495 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/505 ,  A61K31/506 ,  A61K31/53 ,  A61K31/519 ,  A61K31/52 ,  A61K31/7012 ,  A61K31/7028 ,  A61K31/7088 ,  A61K31/713 ,  A61K31/704 ,  A61K45/00 ,  A61P43/00 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/52

摘要： The purpose of the present invention is to provide a screening method that enables efficient discovery of a novel senolytic drug and a senolytic drug obtained by the screening method. The present invention pertains to a senolytic drug that inhibits binding between PGAM and Chkl and also selectively kills senescent cells. More particularly, the senolytic drug of the present invention contains, as an active ingredient, at least one selected from the group consisting of an mRSK1 kinase inhibitor, an Fak kinase inhibitor, an inhibitor of signaling pathways involving Fak kinase, a CDK inhibitor, a calcium antagonist agent, an inotropic glycoside, a DNA damaging agent, an antimicrobial agent, an Aurora kinase inhibitor, a flavonoid, a PI3K kinase inhibitor, an HDAC inhibitor, a therapeutic agent for age-related macular degeneration, a p38 MAPK inhibitor, an mTOR inhibitor, a tyrosine kinase inhibitor, a Bcl-2 inhibitor, statin, a serotonin receptor antagonist, other kinase inhibitors and Nutlin-3b.